Passer à la navigation principale Passer à la recherche Passer au contenu principal

Management of ocular toxoplasmosis in France: Results of a modified Delphi study

Titre traduit de la contribution: Prise en charge de la toxoplasmose oculaire en France: résultats d'une étude Delphi modifiée
  • M. Schaeffer
  • , L. Ballonzoli
  • , D. Gaucher
  • , C. Arndt
  • , K. Angioi-Duprez
  • , R. Baudonnet
  • , B. Bodaghi
  • , A. Bron
  • , F. Chiambaretta
  • , B. Cimon
  • , C. Chiquet
  • , C. Creuzot-Garcher
  • , V. Daien
  • , A. S. Deleplanque
  • , H. Fricker-Hidalgo
  • , E. Hadjadj
  • , S. Houze
  • , T. Ifrah
  • , J. F. Korobelnik
  • , P. Labalette
  • M. Laure Le Lez, C. L'Ollivier, M. Mercie, F. Mouriaux, L. Paris, H. Pelloux, C. Pomares, J. C. Quintyn, M. B. Rougier, A. Rousseau, V. Soler, M. Talmud, I. Villena, O. Villard, C. Speeg-Schatz, T. Bourcier, A. Sauer
  • Strasbourg University Hospital
  • CHU de Reims
  • Clinical Investigation Center
  • Limoges University Hospital
  • Groupe Hospitalier Lariboisiere-Fernand Widal Assistance Publique-Hopitaux de Paris (AP-HP)
  • Centre Hospitalier Universitaire de Dijon
  • France; Université Clermont Auvergne
  • CHRU Strasbourg
  • CHU Grenoble
  • University Hospital of Montpellier
  • CHU Lille
  • Assistance publique des Hôpitaux de Marseille
  • Medical and Infectious Diseases ICU (MI2)
  • Centre Hospitalier Universitaire
  • CHU Bordeaux
  • CHRU de Tours
  • CHU Marseille
  • Université et CHU de Poitiers
  • CHU de Rennes
  • Sorbonne Université
  • CHU de Nice
  • Pneumologie & Médecine Nucléaire CHU
  • Assistance Publique-Hôpitaux de Paris
  • CHU Toulouse
  • Univ. de Reims Champagne Ardenne

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

Résumé

Objective: To evaluate diagnostic and therapeutic practices and then establish a consensus on the management of ocular toxoplasmosis in France through a Delphi study. Materials and methods: Twenty-three French experts in ocular toxoplasmosis were invited to respond to a modified Delphi study conducted online, in the form of two questionnaires, in an attempt to establish a consensus on the diagnosis and management of this pathology. The threshold for identical responses to reach consensus was set at 70 %. Results: The responses of 19 experts out of the 23 selected were obtained on the first questionnaire and 16 experts on the second. The main elements agreed upon by the experts were to treat patients with a decrease in visual acuity or an infectious focus within the posterior pole, to treat peripheral lesions only in the presence of significant inflammation, the prescription of first-line treatment with pyrimethamine-azithromycin, the use of corticosteroid therapy after a period of 24 to 48 hours, the prophylaxis of frequent recurrences (more than 2 episodes per year) with trimethoprim-sulfamethoxazole as well as the implementation of prophylactic treatment of recurrences in immunocompromised patients. On the other hand, no consensus emerged with regard to the examinations to be carried out for the etiological diagnosis (anterior chamber paracentesis, fluorescein angiography, serology, etc.), second-line treatment (in the case of failure of first-line treatment), or treatment of peripheral foci. Conclusion: This study lays the foundations for possible randomized scientific studies to be conducted to clarify the management of ocular toxoplasmosis, on the one hand to confirm consensual clinical practices and on the other hand to guide practices for which no formal consensus has been demonstrated.

Titre traduit de la contributionPrise en charge de la toxoplasmose oculaire en France: résultats d'une étude Delphi modifiée
langue originaleAnglais
Pages (de - à)413-422
Nombre de pages10
journalJournal Francais d'Ophtalmologie
Volume45
Numéro de publication4
Les DOIs
étatPublié - 1 avr. 2022
Modification externeOui

Empreinte digitale

Examiner les sujets de recherche de « Prise en charge de la toxoplasmose oculaire en France: résultats d'une étude Delphi modifiée ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation